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Summary
Background In laboratory animals, exposure to most general anaesthetics leads to neurotoxicity manifested by neuronal 
cell death and abnormal behaviour and cognition. Some large human cohort studies have shown an association 
between general anaesthesia at a young age and subsequent neurodevelopmental deficits, but these studies are prone 
to bias. Others have found no evidence for an association. We aimed to establish whether general anaesthesia in early 
infancy affects neurodevelopmental outcomes.
Methods In this international, assessor-masked, equivalence, randomised, controlled trial conducted at 28 hospitals 
in Australia, Italy, the USA, the UK, Canada, the Netherlands, and New Zealand, we recruited infants of less than 
60 weeks’ postmenstrual age who were born at more than 26 weeks’ gestation and were undergoing inguinal 
herniorrhaphy, without previous exposure to general anaesthesia or risk factors for neurological injury. Patients 
were randomly assigned (1:1) by use of a web-based randomisation service to receive either awake-regional 
anaesthetic or sevoflurane-based general anaesthetic. Anaesthetists were aware of group allocation, but individuals 
administering the neurodevelopmental assessments were not. Parents were informed of their infants group 
allocation upon request, but were told to mask this information from assessors. The primary outcome measure 
was full-scale intelligence quotient (FSIQ) on the Wechsler Preschool and Primary Scale of Intelligence, third 
edition (WPPSI-III), at 5 years of age. The primary analysis was done on a per-protocol basis, adjusted for 
gestational age at birth and country, with multiple imputation used to account for missing data. An intention-to-
treat analysis was also done. A difference in means of 5 points was predefined as the clinical equivalence margin. 
This completed trial is registered with ANZCTR, number ACTRN12606000441516, and ClinicalTrials.gov, 
number NCT00756600.
Findings Between Feb 9, 2007, and Jan 31, 2013, 4023 infants were screened and 722 were randomly allocated: 
363 (50%) to the awake-regional anaesthesia group and 359 (50%) to the general anaesthesia group. There were 
74 protocol violations in the awake-regional anaesthesia group and two in the general anaesthesia group. Primary 
outcome data for the per-protocol analysis were obtained from 205 children in the awake-regional anaesthesia group 
and 242 in the general anaesthesia group. The median duration of general anaesthesia was 54 min (IQR 41–70). The 
mean FSIQ score was 99·08 (SD 18·35) in the awake-regional anaesthesia group and 98·97 (19·66) in the general 
anaesthesia group, with a difference in means (awake-regional anaesthesia minus general anaesthesia) of 0·23 
(95% CI –2·59 to 3·06), providing strong evidence of equivalence. The results of the intention-to-treat analysis were 
similar to those of the per-protocol analysis.
Interpretation Slightly less than 1 h of general anaesthesia in early infancy does not alter neurodevelopmental 
outcome at age 5 years compared with awake-regional anaesthesia in a predominantly male study population.
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Introduction
Concerns about anaesthesia-induced neurotoxicity in the 
developing brain are ongoing.1,2 In animal models, 
exposure to most general anaesthetics at a young age 
results in a range of morphological changes.3 These 
exposed animals, including non-human primates, show 
neuronal cell death, impaired neurogenesis, glial death, 
and abnormal axon formation.4–7 In some animal models, 
anaesthesia exposure in infancy has also been associated 
with altered behaviours, including heightened emotional 
reactivity to threats, and impaired learning and memory 
formation persisting into early adulthood.8,9 It is unclear 
how these findings from animal model translate to 
humans, whose development is more complex than that 
of other animals.
Human cohort studies have yielded mixed and con-
flicting evidence for associations between exposure to 
anaesthesia in early childhood and various adverse 
neurodevelopmental outcomes.10 On the basis of preclinical 
and clinical findings, the US Food and Drug Administration 
has mandated warning labels on most general anaesthetics 
used in children.11,12 There have also been numerous calls 
for more definitive research to assess whether anaesthetic 
exposure in early childhood has a clinically relevant effect 
on neurodevelopment in humans.13,14
Drawing any conclusions about causation from cohort 
studies is inherently difficult because of probable con-
founding. Therefore, we did a randomised controlled 
trial—the neurodevelopmental outcome after general 
anaesthesia or awake-regional anaesthesia in infancy 
(GAS) trial—with an equivalence design to show whether 
an exposure to general anaesthesia in infants causes 
clinically significant long-term neurodevelopmental 
changes. We included children undergoing inguinal 
herni orrhaphy, a surgery for which either a volatile 
anaesthetic (which has been shown to cause injury and 
neuro behavioural deficits in animal models) or an awake-
regional technique (which does not cause neuronal 
injury in animal models) can be used.15 Our hypothesis 
was that there would be no clinically important 
differences in neurodevelopmental outcome between 
general anaes thesia and regional anaesthesia. A finding 
of equivalence would result in clinicians no longer 
subjecting children to the various risks of delaying 
surgery, and anaesthetists not avoiding general 
anaesthesia by using alternative, and potentially less well 
established, anaesthetic techniques. As we reported 
previously,16 neurodevelopmental outcome at age 2 years 
(assessed with the Bayley Scales of Infant and Toddler 
Development III) did not significantly differ between 
the awake-regional and general anaesthesia groups. 
Assessment at 2 years was regarded as an interim or 
secondary outcome because neurodevelopmental delays 
can be measured more accurately at 5 years of age. Data 
relating to apnoea in the immediate postoperative period, 
intraoperative blood pressure, regional anaes thesia, and 
Research in context
Evidence before this study
We searched MEDLINE and the Cochrane controlled trials register 
(from their inception to May 20, 2018) for original research and 
meta-analyses describing the association between anaesthetic 
exposure during childhood and neurodevelopmental outcome. 
The search terms used were “anesthesia” AND “child 
development”; OR “anesthesia” AND “learning disorders”. 
No randomised trials were found, except for the interim analysis 
of the GAS trial published in 2016, which found equivalence in 
Bayley-III scores between infants exposed to either regional or 
general anaesthesia. Most large cohort studies reported an 
association between surgery before age 4 years and an increased 
risk for a later diagnosis of behavioural problems or poor 
academic attainment. In some studies, increased risk was very 
small, and in others was seen only after multiple exposures. 
Several, but not all, of the cohort studies found no association 
with neurocognitive outcome as assessed by formal intelligence 
quotient (IQ) testing. Weaknesses in these cohort studies 
included confounding, bias, heterogeneous populations at the 
time of exposure, and heterogeneous outcome measures, 
making interpretation and generalisation problematic.
Added value of this study
We report the 5-year neurodevelopmental outcome results 
for the GAS trial, the first randomised controlled trial 
designed to assess the effect of general anaesthesia in infancy 
on neurodevelopmental outcome. We used the most reliable 
and validated measure of general intellectual ability, the 
full-scale IQ score on the Wechsler Preschool and Primary 
Scale of Intelligence, third edition, and found strong evidence 
for equivalence between awake-regional anaesthesia and 
slightly less than 1 h of general anaesthesia. No significant 
differences were seen in a range of other neurocognitive and 
behavioural measures.
Implications of all the available evidence
This randomised controlled trial provides strong evidence that 
1 h of exposure to a general anaesthetic during early infancy 
does not cause measurable neurocognitive or behavioural 
deficits at age 5 years. These results are consistent with the 
MASK and PANDA cohort studies. Nearly half the general 
anaesthetics in infancy are used for less than 1 h duration, and 
this study should therefore allay some of the concerns 
generated by preclinical data and previous cohort studies. 
This trial does not address the possibility that longer or 
repeated anaesthesia exposures in early childhood are 
detrimental. The trial was also conducted in a predominantly 
male population, and thus further research is needed to answer 
these questions in female children and those with multiple and 
prolonged exposures.
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surgical outcomes from the GAS trial were also published 
previously.17–20 In this Article, we report the primary 
outcome of the trial, in addition to various secondary 
outcomes, measured at age 5 years. 
Methods
Study design and participants
We did a multicentre, international, parallel-group, 
random ised, assessor-masked, controlled, equivalence trial 
comparing neurodevelopmental outcome at age 5 years, in 
infants randomised to receive awake-regional anaesthesia 
or general anaesthesia for inguinal herniorrhaphy. The 
trial was done at 28 hospitals in Australia, Italy, the USA, 
the UK, Canada, the Netherlands, and New Zealand. 
Institutional review board or human research ethics 
committee approval was obtained at each site, and written 
informed consent was obtained from the infant’s parents 
or guardians. A summary of the protocol is available 
online.21
Infants were included if they were aged 60 weeks’ 
postmenstrual age or less, born at greater than 26 weeks’ 
gestation, and scheduled for inguinal herniorrhaphy. 
Exclusion criteria were any contraindication for either 
anaesthetic technique used in the study, a history of 
congenital heart disease requiring surgery or pharma-
cotherapy, mechanical ventilation immediately before 
surgery, known chromosomal abnormalities or other 
known acquired or congenital abnormalities that might 
affect neurodevelopment, previous exposure to volatile 
general anaesthesia or benzodiazepines as a neonate or 
in the third trimester in utero, any known neurological 
injury such as cystic periventricular leukomalacia or 
grade three or four intraventricular haemorrhage, any 
social or geographical factor that might make follow-up 
difficult, or having a primary language at home in a 
region where neurodevelopmental tests were not 
available in that language. We identified eligible infants 
from operating room schedules or at preadmission 
clinics and recruited in the clinic or in the preadmission 
areas of the operating floor.
Randomisation and masking
Infants were randomly assigned (1:1) to receive either 
general anaesthesia or awake-regional anaesthesia using 
a 24-h web-based randomisation service managed by the 
Data Management and Analysis Centre, Department 
of Public Health, University of Adelaide, Australia. 
Randomisation was done in blocks of two or four in a 
computer-generated random-allocation sequence, with 
stratification by site and by gestational age at birth 
(26 weeks to 29 weeks and 6 days, 30 weeks to 36 weeks 
and 6 days, and 37 weeks or more). The anaesthetist was 
aware of group allocation, but individuals who admin-
istered the neurodevelopmental assessments were not. 
Parents who asked about their infant’s group allocation 
were informed and told to mask this information from 
assessors. After assessments were completed, parents 
and assessors were asked if they were aware of group 
allocation.
Procedures
The awake-regional group received a spinal, caudal, or 
combined caudal and spinal anaesthetic, according to 
institutional preferences. Bupivacaine or levobupivacaine 
at a dose of 0·75–1 mg/kg was administered for spinal 
anaesthesia. Caudal anaesthesia was with 0·25% bupi-
vacaine or levobupivacaine up to a total dose of 2·5 mg/kg. 
In the USA, several patients in whom it was known 
that the surgery would take longer than 1 h were also 
administered 3% chloroprocaine via a caudal catheter 
(loading bolus of 3% chloroprocaine 1 mL/kg over several 
minutes and then an infusion at 1–2 mL/kg per h). 
Additional ilioinguinal and field blocks were used 
according to surgical preference. Oral sucrose was given 
if the child was unsettled, but no other pharmacological 
sedation was permitted. Infants who showed agitation 
that was not resolved by oral sucrose, or in whom the 
awake-regional anaesthetic was inadequate, were treated 
with sevoflurane. The administration of sevoflurane, 
nitrous oxide, or any other general anaesthetic in this 
group was considered a protocol violation.
The general anaesthesia group received sevoflurane for 
induction and maintenance in a mix of air and oxygen. 
The concentration of sevoflurane, choice of airway device, 
ventilation technique, and use of neuromuscular blocking 
agents were left to the preference of the anaesthetist. 
Supplemental opioids and nitrous oxide were not allowed, 
but caudal, ilioinguinal–iliohypogastric, or field blocks 
with bupivacaine were permitted to provide postoperative 
analgesia.
Both groups could also be given oral, rectal, or in-
travenous paracetamol. Monitoring and recording were 
identical in both groups, with heart rate, blood pressure, 
oxygen saturation, and expired sevoflurane concentrations 
(where applicable) every 5 min. In both groups, intra-
operative serum glucose values were measured after 
induction, and rescue protocols for hypoglycaemia, hypo-
tension, and hypoxaemia were applied as appropriate.
Outcomes
The primary outcome measure was the Wechsler 
Preschool and Primary Scale of Intelligence, third edition 
(WPPSI-III) full-scale intelligence quotient (FSIQ) score. 
Secondary outcome measures were selected NEPSY-II 
subtests to assess attention and executive function; the 
Wechsler Individual Achievement Test, second edition 
(WIAT-II), or the BVN (the Italian equivalent of the WIAT-
II); selected subtests of the Children’s Memory Scale 
(CMS); the global executive composite of the Behaviour 
Rating Inventory of Executive Function, Preschool version 
(BRIEF-P); the Adaptive Behaviour Assessment System, 
second edition (ABAS-II); and the Child Behaviour 
Checklist caregiver questionnaire (CBCL). Neuropsychol-
ogical as sessments were to be done within 4 months of 
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the child turning 5 years of age. The total assessment 
time was estimated to take around 3 h to complete, and 
assessments were done at each site by a child psychologist 
certified to conduct the tests. Quality control was 
maintained by a national co ordinating psychologist. 
Participatory tests were administered by the psychologist, 
and a parent or caregiver completed the informant report 
questionnaires. Parents were asked if their child had been 
diagnosed with cerebral palsy, autism spectrum disorder, 
or attention-deficit hyperactivity disorder (ADHD), or had 
any other neuro developmental issues. They were also 
asked if the child had received any neurodevelopmental 
interventions. Hearing or vision problems were also 
noted. Demographic data, family structure, and medical 
history since randomisation were recorded, and a brief 
physical and neurological examination was done for each 
patient. All these outcome measures were prespecified in 
the protocol.
All study data were sent to the Murdoch Children’s 
Research Institute in Melbourne, Australia. All data 
forms were checked by a research assistant not involved 
in primary data collection or entry. Data on test forms that 
were not completed according to test manual instructions 
were rejected.
An independent data safety monitoring committee 
met around every 6 months during recruitment. Site 
visits were done by the national coordinating teams for 
each country annually or biennially, and site visits at the 
national coordinating sites were done by principal 
investigators from other nations to check the validity of 
data. Summary data by allocation were presented to this 
committee.
Statistical analysis
The study hypothesis was that WPPSI-III FSIQ score at 
age 5 years is equivalent in infants who have received 
awake-regional anaesthesia or general anaesthesia for 
inguinal herniorrhaphy. Because this was an equivalence 
study, the outcome was analysed on an per-protocol basis 
to ensure a conservative estimate of the treatment effect 
in the direction of non-equivalence. Although it is best 
practice to analyse outcomes on an intention-to-treat 
basis, there were unavoidable protocol violations in this 
study (the majority of which were in babies allocated to 
receive regional anaesthesia who had some exposure to 
general anaesthesia, particularly if the awake-regional 
anaesthesia failed). If all infants were analysed on an 
intention-to-treat basis, this switching from one random-
ised treatment to the other could dilute the potential 
effect of general anaesthesia and thus bias the trial 
towards equivalence.22
Equivalence was defined a priori as the 95% CI of the 
difference in means of the FSIQ lying within –5 and +5 IQ 
points. Intention-to-treat analyses were also planned. All 
CIs are two-sided.
The sample size was based on the primary outcome. 
Assuming an expected difference of 1 standardised score 
point, a standard deviation of 15, and a 90% chance that 
a 95% CI will exclude a difference of more than 5 points 
(the largest difference acceptable to show equivalence), 
the trial would need 598 infants. The sample size 
formula used was based on approximations to the 
normal distribution, and used a two one-sided test 
procedure. Enrolling roughly 720 participants would 
allow for 10% loss to follow-up and 10% with a major 
protocol violation.
We used multiple imputation under a multivariate 
normal distribution to impute missing outcome data in 
the primary analysis of all outcomes, with a sensitivity 
analysis done on only complete cases. Multiple impu-
tations were done with the mi impute mvn statement in 
Stata (version 14.2). The variables used in the multiple 
imputation models included baseline, post-random isation, 
2-year cognitive variables, and 5-year outcome variables. 
A number of prespecified variables were used as possible 
predictor variables within the imputation approach, 
Figure: Trial profile
WPPSI=Weschler Preschool and Primary Scale of Intelligence. *Five surgeries cancelled, 69 general anaesthesia 
required. †Two surgeries cancelled.
4023 patients screened
3301 excluded
 1085 met predefined exclusion criteria
 1084 surgeon or anaesthesiologist did not agree to inclusion
 728 parent or guardian did not consent
 404 other reasons (mostly logistical)
722 randomly allocated
2 misrandomised
74 protocol violations*
 22 not assessed
 19 lost to follow-up
   3 withdrew
 46 completed WPPSI-III
 6 partially assessed
363 to awake-regional anaesthesia group 359 to general anaesthesia group
361 included in intention-to-treat analysis
1 withdrew consent
2 protocol violations†
 2 not assessed 
 1 lost to follow-up
 1 withdrew
358 included in intention-to-treat analysis
287 included in per-protocol analysis 356 included in per-protocol analysis
205 complete case assessments 242 complete case assessments
82 without complete case assessment
 69 not assessed
 50 lost to follow-up
 19 withdrew
 13 partially assessed
114 without complete case assessment
 95 not assessed
 78 lost to follow-up
 17 withdrew
 19 partially assessed
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including baseline variables (anaesthesia group, country, 
sex, gestational age at birth, birthweight, antenatal steroids 
received by mother, mother’s education, and maternal age 
<21 years), variables at surgery (need for fluid bolus for 
hypotension, duration of surgery, significant postoperative 
apnoea, and age), variables at age 2 years (composite 
cognitive, language, motor and social–emotional score on 
the Bayley Scales of Infant and Toddler Development, 
third edition; any additional anaesthetic exposures 
since the inguinal herniorrhaphy; any inter ventions for 
neurodevelopmental problems; and any other neurological 
abnormality), and variables at age 5 years (WPPSI-III 
FSIQ, any chronic illness, any additional anaesthetic 
exposures since the inguinal herniorrhaphy, total length 
of any readmission to hospital, cerebral palsy, any inter-
ventions for neurodevelopmental problems, and any other 
Per protocol Intention to treat
Awake-regional 
anaesthesia (n=287)
General anaesthesia 
(n=356)
Awake-regional 
anaesthesia (n=361)
General anaesthesia 
(n=358)
Baseline demographics
Sex
Male 232/287 (81%) 304/356 (85%) 294/360 (82%) 306/358 (85%)
Female 55/287 (19%) 52/356 (15%) 66/360 (18%) 52/358 (15%)
Chronological age at surgery, days 68·9 (30·8), n=287 71·1 (31·7), n=356 70·1 (31·8), n=358 71·0 (31.7), n=357
Postmenstrual age at surgery, days 317·2 (31.9), n=287 319·7 (31.8), n=356 318·3 (32.6), n=357 319·5 (32·0), n=357
Weight of child at surgery, kg 4·2 (1·1), n=287 4·3 (1·1), n=356 4·2 (1·1), n=359 4·3 (1·1), n=357
Pregnancy and birth details
Postmenstrual age at birth, days 248·2 (28.7), n=287 248·6 (27·2), n=356 248·3 (28.5), n=360 248·6 (27·2), n=358
Prematurity (born at <37 weeks’ 
gestation)
160/287 (56%) 195/356 (55%) 198/361 (55%) 196/358 (55%)
Birthweight, kg 2·3 (0·9), n=287 2·3 (0·9), n=355 2·4 (0·9), n=359 2·3 (0·9), n=357
Z score for birthweight –0·7 (1·3), n=287 0·7 (1·3), n=355 –0·7 (1·2), n=359 –0·7 (1·3), n=357
Apgar score at 1 min; median (IQR) 9 (7–9), n=237 8·5 (7–9), n=282 9 (7–9), n=292 9 (7–9), n=284
Apgar score at 5 min; median (IQR) 9 (9–10), n=237 9 (9–10), n=282 9 (9–10), n=292 9 (9–10), n=284
One of a multiple pregnancy 52/284 (18%) 61/356 (17%) 62/360 (17%) 62/358 (17%)
Mother received partial course antenatal 
steroids
16/287 (6%) 19/356 (5%) 20/360 (6%) 19/358 (5%)
Mother received complete course 
antenatal steroids
95/287 (33%) 98/356 (28%) 114/360 (32%) 98/352 (28%)
Mother diagnosed with chorioamnionitis 10/287 (3%) 12/356 (3%) 11/360 (3%) 12/358 (3%)
Prolonged (>24 h) rupture of the 
membranes
28/287 (10%) 34/356 (10%) 32/360 (9%) 34/350 (10%)
Mother diagnosed with pre-eclampsia 50/287 (17%) 68/356 (19%) 60/360 (17%) 68/358 (19%)
Sepsis during pregnancy 36/286 (13%) 50/356 (14%) 43/358 (12%) 50/358 (14%)
Mode of delivery of birth
Cephalic vaginal 135/287 (47%) 157/356 (44%) 169/360 (47%) 157/358 (44%)
Breech vaginal 1/287 (<1%) 6/356 (2%) 3/360 (1%) 6/358 (2%)
Compound vaginal 2/287 (1%) 4/356 (1%) 3/360 (1%) 4/358 (1%)
Caesarean section 149/287 (52%) 189/356 (53%) 185/360 (51%) 191/358 (53%)
Caesarean section and mother went 
into labour
42/287 (15%) 58/356 (16%) 52/360 (14%) 59/358 (16%)
Mother exposed to nitrous oxide during 
delivery
48/275 (17%) 62/344 (18%) 61/344 (18%) 62/346 (18%)
Intraventricular haemorrhage 7/286 (2%) 6/356 (2%) 8/359 (2%) 6/358 (2%)
Grade 1 5/286 (2%) 6/356 (2%) 5/359 (1%) 6/358 (2%)
Grade 2 2/286 (1%) 0/356 2/359 (1%) 0/358
Retinopathy of prematurity 17/198 (9%) 16/256 (6%) 20/246 (8%) 16/257 (6%)
Hearing defects detected by perinatal 
screening
7/253 (3%) 10/356 (3%) 8/316 (3%) 10/325 (3%)
Patent ductus arteriosus diagnosed 23/286 (8%) 21/355 (6%) 27/359 (8%) 21/357 (6%)
Never treated 9/286 (3%) 9/355 (3%) 11/359 (3%) 9/357 (3%)
Treated with NSAIDs 14/286 (5%) 10/355 (3%) 16/359 (4%) 10/357 (3%)
(Table 1 continues on next page)
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neurological abnormality). Since most of these variables 
also have missingness, they were also imputed where 
necessary. With many missing observations, these multiple 
imputation models did not always converge, in which case, 
to ensure convergence of models, applicable variables 
were not included. The variables used in the analysis 
model were always included in the imputation models.
For all continuous outcomes, linear regression was 
used with the factor variables anaesthesia group (awake-
regional anaesthesia and general anaesthesia), with 
gestational age at birth and country as fixed effects. 
Adjusted mean differences are presented with 95% CIs.
All binary outcomes were analysed with generalised 
linear models with binomial link function to enable 
estimation of risk ratios, adjusting for the same factors as 
for the linear regression. Risk ratios are presented with 
95% CIs.
The following subgroup analyses were prespecified in 
the statistical analysis plan: country, duration of surgery 
(≥120 min or <120 min), and age at surgery (>70 days or 
≤70 days). A subgroup analysis by ex-term versus 
ex-preterm (born at <37 weeks’ gestation) was also done 
post hoc. p values for the interactions are shown along 
with subgroup treatment effect esti mates and 95% CIs. 
All analyses were done in Stata (version 14.2).
The GAS trial is registered in Australia and New Zealand 
at ANZCTR (number ACTRN12606000441516, first reg-
istered Oct 16, 2006); in the USA at ClinicalTrials.gov 
(number NCT00756600, first registered on Sept 18, 2008); 
and in the UK at UK Clinical Research Network (number 
6635; ISRCTN ID 12437565; MREC number 07/S0709/20). 
The statistical analysis plan is available at ANZCTR 
(number ACTRN12606000441516).23
Role of the funding source
The funders of this study had no role in study design, data 
collection, data analysis, data interpretation, writing of the 
manuscript, or the decision to submit this manuscript 
for publication. AG had complete access to all the data. 
All other authors have access to the data on request. All 
Per protocol Intention to treat
Awake-regional 
anaesthesia (n=287)
General anaesthesia 
(n=356)
Awake-regional 
anaesthesia (n=361)
General anaesthesia 
(n=358)
(Continued from previous page)
Familial demographics
Primary language(s) only spoken* 252/287 (88%) 305/356 (86%) 311/360 (86%) 307/358 (86%)
Maternal age at birth >21 years 273/286 (95%) 339/356 (95%) 339/358 (95%) 341/358 (95%)
Family structure two caregivers together 
(at birth)
261/286 (91%) 324/356 (91%) 328/359 (91%) 326/358 (91%)
Maternal education
Completed tertiary studies 150/286 (52%) 171/354 (48%) 181/358 (51%) 171/358 (48%)
Continuing tertiary studies 50/286 (17%) 67/354 (19%) 68/358 (19%) 67/358 (19%)
Completed 11 or 12 years of education 62/286 (22%) 83/354 (23%) 77/358 (22%) 87/358 (24%) 
Did not complete 11 years of 
education
25/286 (9%) 33/354 (9%) 32/358 (9%) 34/358 (9%)
Anaesthesia details
Blood glucose level, mmol/L; 
median (IQR)
5·4 (4·7–6·1), n=255 5·5 (4·8–6·4), n=314 5·4 (4·7–6·2), n=312 5·5 (4·8–6·4), n=314
Intravenous rescue glucose given 2/282 (1%) 4/356 (1%) 2/350 (1%) 4/356 (1%)
Haemoglobin concentration, g/100 mL 10·3 (2·1), n=250 10·2 (2·0), n=307 10·3 (2·1), n=305 10·2 (2·0), n=307
Need for fluid bolus for hypotension 15/287 (5%) 59/356 (17%) 21/355 (6%) 59/356 (17%)
Vasoactive drugs given (including 
atropine)
4/287 (1%) 17/356 (5%) 6/355 (2%) 17/356 (5%)
Duration of surgery, min; median (IQR) 26·0 (19·0–35·0), n=286 28·0 (20·0–40·0), n=355 28·0 (20·0–38·0), n=353 28·0 (20·0–40·0), n=355
Duration of sevoflurane exposure, min; 
median (IQR)
·· 54·0 (41·0–70·0), n=356 42·0 (31·0–62·5), n=67† 54·0 (41·0–70·0), n=356
Mean end tidal sevoflurane 
concentration, %
·· 2·6 (0·7), n=356 2·3 (0·8), n=67† 2·6 (0·7), n=356
Total concentration × h of exposure ·· 2·6 (1·1), n=356 1·9 (1·0), n=67† 2·6 (1·1), n=356
Any significant apnoea to 12 h 
post operation‡
6/287 (2%) 15/356 (4%) 10/360 (3%) 15/358 (4%)
Data are n/N (% of non-missing data) or mean (SD), unless otherwise specified. NSAIDs=non-steroidal anti-inflammatory drugs. *The primary language spoken at home is the 
primary language in each country in which the Bayley was conducted (eg, in Italy, it was done in Italian). †For those cases that received sevoflurane. ‡Significant apnoea defined 
as a pause in breathing for more than 15 s or more than 10 s if associated with oxygen saturation less than 80% or bradycardia (20% decrease in heart rate).
Table 1: Baseline demographic data
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Per protocol Intention to treat
Awake-regional 
anaesthesia group 
(n=287)
General anaesthesia group 
(n=356)
Awake-regional 
anaesthesia group 
(n=361)
General anaesthesia 
group (n=358)
Assessment details
Location of 5-year assessment at hospital 198/216 (92%) 228/257 (89%) 246/268 (92%) 228/257 (89%)
Family demographics at 5 years
Paid employment is the main family income 201/214 (94%) 237/256 (93%) 243/266 (91%) 237/256 (93%)
Family structure two caregivers living together 194/214 (91%) 223/257 (87%) 230/266 (86%) 223/257 (87%)
Number of children at home
1 50/214 (23%) 53/257 (21%) 63/266 (24%) 53/257 (21%)
2 95/214 (44%) 133/257 (52%) 120/266 (45%) 133/257 (52%)
3 56/214 (26%) 48/257 (19%) 67/266 (25%) 48/257 (19%)
≥4 13/214 (6%) 23/257 (9%) 16/266 (6%) 23/257 (9%)
Birth order
1 113/211 (54%) 137/257 (53%) 137/261 (52%) 137/257 (53%)
2 69/211 (33%) 81/257 (32%) 87/261 (33%) 81/257 (32%)
≥3 29/211 (14%) 39/257 (15%) 37/261 (14%) 39/257 (15%)
Age at follow-up assessment 5·2 (0·2), n=217 5·3 (0·3), n=258 5·2 (0·2), n=269 5·3 (0·3), n=258
Events since original anaesthesia
Any hospitalisation 101/199 (51%) 129/250 (52%) 131/249 (53%) 129/250 (52%)
Number of days hospitalised
0 105/169 (62%) 127/213 (60%) 125/213 (59%) 127/213 (60%)
1 22/169 (13%) 30/213 (14%) 34/213 (16%) 30/213 (14%)
2 11/169 (7%) 13/213 (6%) 13/213 (6%) 13/213 (6%)
≥3 31/169 (18%) 43/213 (20%) 41/213 (19%) 43/213 (20%)
Any anaesthesia 71/102 (70%) 71/111 (64%) 89/133 (67%) 71/111 (64%)
Number of anaesthetics
0 104/156 (67%) 132/181 (73%) 131/197 (66%) 134/183 (73%)
1 28/156 (18%) 27/181 (15%) 37/197 (19%) 27/183 (15%)
2 11/156 (7%) 11/181 (6%) 14/197 (7%) 11/183 (6%)
≥3 13/156 (8%) 11/181 (6%) 15/197 (8%) 11/183 (6%)
Any seizures 14/173 (8%) 17/217 (8%) 17/217 (8%) 17/217 (8%)
Events since 2-year assessment
Child had a head injury that involved loss of 
consciousness
2/213 (1%) 2/266 (1%) 3/265 (1%) 2/257 (1%)
Child has any chronic illness 38/213 (18%) 43/258 (17%) 48/265 (18%) 43/258 (17%)
Child had any prescribed medication for 2 months 
or longer
37/214 (17%) 44/257 (17%) 44/266 (17%) 44/257 (17%)
Child has had an intervention for 
neurodevelopmental issues
49/213 (23%) 60/257 (23%) 64/264 (24%) 60/257 (23%)
Speech therapy 36/217 (17%) 48/259 (19%) 50/269 (19%) 48/259 (19%)
Physiotherapy 11/217 (5%) 17/259 (7%) 12/269 (4%) 17/259 (7%)
Occupational therapy 18/217 (8%) 20/259 (8%) 21/269 (8%) 20/259 (8%)
Psychology 7/217 (3%) 6/259 (2%) 8/269 (3%) 6/259 (2%)
Other interventions 9/217 (4%) 16/259 (6%) 12/269 (4%) 16/259 (6%)
Child attends play group or child care on a regular 
basis
186/213 (87%) 231/257 (90%) 234/265 (88%) 231/257 (90%)
Physical examination
Height, cm 110·8 (5·5), n=207 110·8 (5·5), n=237 110·8 (5·4), n=254 110·8 (5·5), n=237
Weight, kg 19·3 (3·3), n=206 19·4 (2·8), n=236 19·4 (3·2), n=253 19·4 (2·8), n=236
Head circumference, cm 51·6 (1·8), n=194 51·2 (2·6), n=224 51·6 (1·8), n=241 51·2 (2·6), n=224
Arm circumference, cm 17·6 (1·9), n=191 17·4 (1·7), n=219 17·6 (1·9), n=233 17·4 (1·7), n=219
Data are n/N (% of non-missing data) or mean (SD).
Table 2: Demographic data at 5-year assessment
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authors were responsible for the decision to submit this 
manuscript for publication.
Results
Between Feb 9, 2007, and Jan 31, 2013, 4023 infants were 
screened for eligibility, and 722 infants were recruited at 
28 centres in seven countries (appendix). 363 children 
were randomly allocated to the awake-regional anaesthesia 
group and 359 to the general anaesthesia group. After 
two misrandomisations and one withdrawal of consent 
by the family (post-randomisation and pre-surgery), 
361 children were included in the intention-to-treat 
analysis for the awake-regional anaesthesia group and 
358 children were included for the general anaesthesia 
group. 76 patients with protocol violations were excluded, 
leaving 287 patients in the awake-regional anaesthesia and 
356 in the general anaesthesia group in the per-protocol 
analysis (figure). Demographic data at baseline and at the 
5-year assessment are shown in table 1 and table 2.
The 5-year follow-up assessments were done between 
March 13, 2012, and April 27, 2018. 91 families were lost 
to follow-up in the awake-regional anaesthesia group and 
97 in the general anaesthesia group (74% follow-up). Of 
those who attended for assessment, the WPPSI-III FSIQ 
was complete for 205 in the awake-regional anaesthesia 
group and 242 in the general anaesthesia group. Num-
bers lost to follow-up and numbers of complete case 
assessments are listed for each site in the appendix.
When multiple imputation was used to account for 
miss ing data, WPPSI-III FSIQ means appeared equiv-
alent between the two groups in both the per-protocol 
analysis (adjusted mean difference for awake-regional 
anaesthesia minus general anaesthesia 0·23, 95% CI 
–2·59 to 3·06) and the intention-to-treat analysis (0·16, 
–2·45 to 2·78; table 3). The adjusted mean diff erences also 
suggested equivalence in the complete cases analyses 
(0·63, –2·09 to 3·35 for per-protocol analysis; and 0·27, 
–2·27 to 2·80 for intention-to-treat analysis). In all these 
analyses, the upper and lower bounds of the 95% CIs were 
well within the prespecified 5-point equivalence margin.
There was also evidence for equivalence of the verbal, 
performance, and processing speed composite scores of 
the WPPSI-III, with the 95% CIs for the differences in 
means within 5 points in all analyses. For all the other 
individually administered secondary outcomes (table 3) 
and parent-reported or caregiver-reported outcomes 
(table 4), none of the 95% CIs for the differences in means 
were either entirely above or below 0 in any of the analyses 
(with the exception of NEPSY-II statue scaled score in the 
multiple-imputation intention-to-treat analysis). Although 
an equivalence margin was not prespecified for these 
secondary outcomes, a reasonable assumption of equiv-
alence could be made, as the upper and lower bounds of all 
95% CIs were within a third of an SD for all analyses (the 
equivalence limit prespecified for the primary outcome).
Some of the NEPSY-II subscales had large numbers of 
missing data and the SDs were very large with the 
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multiple imputation models due to the low correlations 
of the variables included in the multiple imputation 
model with the outcome variable, leading to little 
information being recovered by the multiple imputations, 
while additional noise was added.
There was no evidence for any between-group dif-
ferences in the proportion of children reported by a 
parent or caregiver to have been diagnosed with a 
neurodevelopmental disorder, with the 95% CIs of all risk 
ratios crossing 1 (table 5). However, the low prevalence of 
these events limits the inferences that can be drawn 
regarding equivalence.
The subgroup analyses for the primary outcome 
(appendix) showed that the differences between groups 
were similar by age at surgery and prematurity. Small 
sample sizes in some of the countries prevented 
conclusive interpretation of country differences in the 
results. Duration of exposure was not analysed because 
no children had exposures longer than 120 min. The 
p values for treatment-by-country interaction were 0·0496 
(F=1·78) for the complete case analysis and 0·0643 
(F=1·69) for the multiple imputation analysis, providing 
evidence of heterogeneity of the results by country.
The only adverse events during the anaesthesia were 
related to respiratory complications, as described in full 
in a previous publication.17 The frequency of hypotension 
has also been described elsewhere.18
We compared the characteristics of children who 
attended the 5-year follow-up assessment with the baseline 
data of the randomised population and the 2-year out-
come data (for those who attended the 2-year follow-up). 
Although there were differences between the character-
istics of children who attended the 5-year follow-up and 
those who did not, there was similar distibution of both 
scores and lack of attendance between the two anaesthesia 
groups (appendix). Likewise, there was a similar dis-
tribution across groups with respect to unmasking of 
group allocation for children who attended the 5-year 
follow-up (appendix).
Discussion
This randomised trial showed strong evidence for 
equivalence in WPPSI-III FSIQ measured at age 5 years 
between children who received awake-regional anaesthesia 
and general anaesthesia for inguinal herniorrhaphy in 
infancy. In a range of other neuropsychological tests, 
evidence of equivalence can also be reasonably assumed 
because the 95% CIs around the differences in means fell 
within a third of an SD. These results are consistent with 
the previously reported 2-year outcomes of the GAS trial, 
assessed with the Bayley Scales of Infant and Toddler 
Development III.16
We assessed the primary outcome at age 5 years because 
there is robust evidence for the emergence of the unitary 
construct of general intelligence and for the individual 
stability of that construct from middle childhood until 
adulthood. Intelligence quotient (IQ) in children aged 
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5–6 years is strongly correlated with adult IQ.24 IQ at age 
5 years is also highly predictive of later mathematical 
ability, and higher IQ in childhood positively predicts a 
range of benefits in academic, economic, and health 
outcomes across the lifespan.25 The WPPSI-III is a well-
validated, standardised, and reliable test for assessing IQ 
in young children.
The WPPSI-III FSIQ was set as the primary outcome 
because of its strong psychometric properties and 
predictive potential, and also because of preclinical 
data;26 the widespread cortical damage seen in preclinical 
models would probably result in a global decline in 
function, and this decline would be best identified by a 
measure of general intellectual function such as the 
WPPSI-III.
Secondary outcome measures were selected, on the 
basis of known vulnerabilities of the developing brain and 
results of early animal and human studies, to assess a 
broad range of cognitive domains that could potentially be 
affected. In choosing the tests, a number of factors were 
considered: previous studies found deficits in both 
hippocampal and non-hippocampal memory; deficits that 
arise from damage to systems that subserve specific skills 
are spread through various regions of the brain and are 
particularly susceptible to neurological insult (ie, attention, 
information processing, and executive function); there is a 
possibility of a cumulative effect of subtle individual or 
multiple deficits on skill development such as visuomotor 
integration, reading, spelling, and arithmetic; and there is 
previous evidence for social and emotional deficits. 
Specific individually administered tests and informant 
report measures were selected from readily available 
standardised tests that are in common clinical use and 
have documented reliability and validity statistics for use 
in this age group.
Several previous cohort studies have sought to identify 
associations between anaesthesia exposure in early 
childhood and various neurodevelopmental outcomes. 
The PANDA study was an ambidirectional cohort study 
that used a range of neuropsychological tests done at 
8–15 years of age to compare neurodevelopmental out-
comes between children who had previously undergone 
inguinal herniorrhaphy under general anaesthesia and 
their unexposed siblings.27 The study found no evidence 
of group differences in IQ scores or scores from various 
other tests of neurocognitive function and behaviour. 
Similarly, the MASK cohort study found no evidence 
for differences in test scores between children that 
had a single anaesthetic compared with those that had 
no previous anaesthetics, although children that had 
multiple anaesthetics did have an increased risk of 
deficits in processing speed and fine motor outcomes, 
and parents reported increased problems related to 
executive function, behaviour, and reading.28 Other 
cohort studies have found evidence for an association 
between anaesthesia exposure and cognitive, memory, 
listening comprehension, and language deficits.29–32
Several other large population-based data-linkage 
studies have found evidence for an association between 
anaesthesia in early childhood and a very small decrease 
in performance in school grades or school readiness 
tests.33–36 Cohort studies have yielded mixed evidence for 
an association between anaesthesia in early childhood 
and a subsequent diagnosis of ADHD or other learning 
Per protocol Intention to treat
Awake-regional 
anaesthesia group
General 
anaesthesia group
Risk ratio 
(95% CI)
Awake-regional 
anaesthesia group
General 
anaesthesia group
Risk ratio 
(95% CI)
Any developmental issues 25/204 (12%) 21/238 (9%) 1·4 (0·8–2·4) 33/255 (13%) 21/238 (9%) 1·5 (0·9–2·5)
Speech or language issues or 
interventions
18/214 (8%) 17/257 (7%) ·· 24/266 (9%) 17/257 (7%) ··
Psychomotor issues or 
interventions
8/214 (4%) 6/257 (2%) ·· 9/266 (3%) 6/257 (2%) ··
Global developmental delay 2/204 (1%) 0/238 ·· 4/255 (2%) 0/238 ··
Behavioural disorders (ADHD, autism 
spectrum disorder)
8/211 (4%) 15/251 (6%) 0·7 (0·3–1·7) 13/263 (5%) 15/251 (6%) 0·99 (0·5–2·0)
Diagnosed with ADHD 3/214 (1%) 4/257 (2%) ·· 7/266 (3%) 4/257 (2%) ··
Diagnosed with autism spectrum 
disorder
5/211 (2%) 11/251 (4%) ·· 7/263 (3%) 11/251 (4%) ··
Hearing abnormality 8/213 (4%) 11/252 (4%) 0·9 (0·4–2·2) 12/264 (5%) 11/252 (4%) 1·1 (0·5–2·4)
Child has a hearing aid 0/211 3/251 (1%) ·· 0/262 3/251 (1%) ··
Visual defect of any type in either eye 21/213 (10%) 31/254 (12%) 0·8 (0·5–1·3) 28/264 (11%) 31/254 (12%) 0·8 (0·5–1·4)
Legally blind (visual acuity <6/60 in 
both eyes)
0/212 0/254 ·· 0/263 0/254 ··
Cerebral palsy 1/213 (<1%) 3/254 (1%) 0·6 (0·1–5·5) 1/264 (<1%) 3/254 (1%) 0·4 (0·0–3·8)
Frequency data are n/N (% of non-missing data). ADHD=attention-deficit hyperactivity disorder. Risk ratios are presented only for variables prespecified as endpoints in the 
statistical analysis plan. Risk ratios were adjusted for gestational age at birth and country.
Table 5: 5-year non-psychometric outcome data
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disability.37–44 Although there might be an increased risk 
of these diagnoses without an increased risk of worse 
outcomes in neurocognitive testing, other confounding 
factors are a possible explanation for these observed 
associations. The GAS trial found no evidence for an 
increased risk of behavioural disorders such as autism 
spectrum disorder or ADHD; however, the diagnosis of 
ADHD and learning disability is typically made in older 
children, and the low prevalence and consequent low 
power reduced our ability to draw a definitive conclusion.
In all these cohort studies, any associations found 
between exposure and poor outcomes could be explained 
by confounding. For instance, because children receive 
anaesthesia for surgery or invasive investigations, the 
condition warranting the procedure might itself be 
associated with increased risk of adverse neurode-
velopmental outcome. Similarly, children with pre-existing 
but as-yet-undiagnosed behavioural problems might be at 
greater risk of needing the procedure. Furthermore, 
perioperative factors other than anaesthesia could also 
increase the risk of poor neurodevelopmental outcome. In 
most studies, attempts are made to limit the effects of 
known confounders through patient selection, matching, 
and adjustments in the analysis, but the potential influence 
of confounding can never be eliminated. The GAS trial is, 
so far, the only randomised trial to assess the effects of 
anaesthesia on neurodevelopment, and thus provides the 
strongest human evidence.
Several previous cohort studies have found more 
evidence for a detrimental effect after multiple exposures 
compared with a single exposure. In the GAS trial, a 
substantial number of children had subsequent anaes-
thetics. The number of children having subsequent 
anaesthetics was well balanced between groups, and 
exposure to subsequent anaesthetics is therefore unlikely 
to have influenced or biased the results of this trial. We 
also found weak evidence for an interaction between 
country and treatment. The reason for this is not 
immediately apparent and, given the marginal level of 
evidence, this finding should be interpreted with caution.
Despite careful selection of patients, an awake-
regional technique is not always adequate for 
herniorrhaphy. Thus, a substantial number of children 
in the awake-regional anaesthesia group had some 
exposure to general anaesthetics. These children were 
excluded from the per-protocol analysis. The absence of 
any substantive difference between the per-protocol and 
intention-to-treat analyses implies that their exclusion 
did not introduce a bias to the trial. In addition, some 
children were lost to follow-up. Multiple imputation was 
used to reduce the effect of these missing data under 
the missing at random assumption. However, even with 
multiple imputation, the results could be influenced by 
the selective follow-up of participants. Children who 
performed poorly at age 2 years were more likely to be 
lost to follow-up at age 5 years. The reason for this 
finding is unclear; however, it is unlikely to lead to a bias 
as the 2-year outcome was included in the multiple 
imputations model. Overall, although the loss to follow-
up was greater than anticipated in the protocol, the 
boundaries of the 95% CIs fell within the predefined 
bounds of equivalence, indicating that the precision of 
the results was adequate despite this greater-than-
expected loss to follow-up.
Given the nature of the interventions, it was impossible 
to mask the treating surgeons or anaesthetists to group 
allocation. It was also impractical to completely mask 
inquisitive parents, as adhesives used to secure the airway 
usually leave signs of skin irritation in the general 
anaesthesia group, and there would be a puncture mark in 
the back from the spinal needle in the regional anaesthesia 
group. Clinicians making the 5-year assessment were 
masked successfully in most cases. It is unlikely that 
unmasking surgeons, anaesthetists, or parents would bias 
the outcome for the individually administered tests. 
However, when interpreting parent-reported outcomes, 
this potential bias should be considered.
There are several considerations to make when 
assessing the generalisability of the GAS trial. First, the 
population was predominantly male, which was expected 
given the surgical pathology selected to create homo-
geneity within the study sample. Second, the infants were 
exposed over a narrow period of development (early 
infancy), this period being chosen as the period of high 
cerebral vulnerability and because this is when both 
awake-regional anaesthesia and general anaesthesia are 
commonly used for hernior rhaphy. When assessing at 
which age children might be at greatest risk, it is difficult 
to translate data from other animals to humans.13,45 In 
general, because younger animals have been found to be 
at greater risk, it is expected that human infants and 
fetuses are most at risk. Some cohort studies have found 
that children exposed at 2–4 years of age are at greater risk, 
but this might also be explained by confounding factors, 
and is less consistent with the preclinical data.33,34 Third, it 
could be argued that 5 years of age is too early to detect 
long-term neurocognitive outcomes because several 
executive functions and social–emotional skills do not 
develop until later in life. However, our results of 
individually administered, standardised tests and parent 
reports indicate that children who undergo anaesthesia in 
infancy start school life with no neurodevelopmental risk 
factors. Exploration of executive function and social–
emotional functions later in development could be an area 
of future study. Fourth, in this trial, children in the general 
anaesthesia group received only sevoflurane; however, 
there are several other general anaesthetics that are used 
for children, such as isoflurane, desflurane, and propofol. 
No existing preclinical data indicate that any effects seen 
with sevoflurane would be different to the effects seen 
with these other agents, and it is therefore reasonable to 
assume that the GAS trial results would translate to other 
general anaesthetic agents. Some preclinical data show 
that the effect might be greater if multiple agents are 
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given concurrently; therefore, the GAS trial results cannot 
be generalised to situations in which multiple general 
anaesthetic agents are given concurrently. Finally, the 
duration of exposure was on average just under 1 h and 
less than 2 h for all children. Animal data suggest that 
longer exposures are more likely to cause neurotoxicity, 
although there is no clear cutoff for length of exposure 
that does or does not have an effect. The hour of 
anaesthesia received by patients in this study was shorter 
than the exposure used in many of the animal experiments; 
however, the equivalence of animal exposure time to that 
in humans is unknown. Furthermore, the median 
duration of general anaesthesia for children in the 
1·5 million procedures in the National Anesthesia Clinical 
Outcomes Registry (USA) was 57 min, with infants having 
a median duration of 79 min.46 Thus, the duration of 
exposure in the GAS trial is longer than nearly half the 
anaesthetic exposures among small children.
The number of children potentially affected by national 
safety warnings, such as those of the US Food and Drug 
Administration, about the potential neurotoxic of general 
anaesthesia is substantial. During the first 3 years of 
life, about 10% of children from developed countries—
equating to millions of children per year—receive a general 
anaesthetic for a variety of surgical, diagnostic, and medical 
procedures.27,47 Most of these children are healthy and will 
be exposed to a single anaesthetic of short or intermediate 
duration during their childhood.42 Given the high 
prevalence of exposure in early childhood, even small 
effects on brain development due to general anaesthesia 
could have very large public health consequences. 
Furthermore, parents and providers could potentially delay 
necessary procedures in children in an effort to limit 
exposure at a time of cerebral vulnerability, putting some 
children at risk for both medical and developmental 
impairments. The GAS trial, being consistent with data 
from several previous cohort studies, provides strong 
evidence that just under 1 h of general anaesthesia in 
infancy does not cause significant neurocognitive or 
behavioural deficits.
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